Atara Biotherapeutics Inc

NASDAQ: ATRA
$0.72
+$0.02 (+3.0%)
Closing price April 23, 2024
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.

Beyond Mesothelioma, Multiple Sclerosis Could Help Atara's Stock Soar Exponentially
On Tuesday, Canaccord Genuity reiterated its rating on Atara Biotherapeutics and raised its wildly bullish target price even higher.
Jon C. Ogg
Published:

Should Atara Bio's Stock Volatility Consider Any Valuation at All on Multiple Sclerosis?
Atara Biotherapeutics finds itself caught between a rock and a hard place after Friday's drug study news concerning its treatment for multiple sclerosis.
Jon C. Ogg
Published: